Empiric guideline-recommended weight-based vancomycin dosing and mortality in methicillin-resistant Staphylococcus aureus bacteremia: a retrospective cohort study
1 Department of Pharmacy Practice, Texas Tech University Health Sciences Center, School of Pharmacy, Dallas, USA
2 Department of Clinical Sciences, University of Texas Southwestern, Dallas, USA
3 Department of Pharmacy Practice, Texas Tech University Health Sciences Center, School of Pharmacy, Amarillo, USA
4 Division of Pharmacotherapy, University of Texas, Austin, USA
5 Department of Internal Medicine, Texas Tech University Health Sciences Center, School of Medicine, Amarillo, USA
6 University of Texas Southwestern, Department of Internal Medicine, Dallas, USA
7 University of Wyoming School of Pharmacy, Swedish Family Medicine Residency Program, Englewood, USA
8 University of Kentucky Healthcare, Lexington, USA
9 Wayne State University Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, USA
10 Mission Regional Medical Center, Mission, USA
BMC Infectious Diseases 2012, 12:104 doi:10.1186/1471-2334-12-104Published: 27 April 2012
No studies have evaluated the effect of guideline-recommended weight-based dosing on in-hospital mortality of patients with methicillin-resistant Staphylococcus aureus bacteremia.
This was a multicenter, retrospective, cohort study of patients with methicillin-resistant Staphylococcus aureus bacteremia receiving at least 48 hours of empiric vancomycin therapy between 01/07/2002 and 30/06/2008. We compared in-hospital mortality for patients treated empirically with weight-based, guideline-recommended vancomycin doses (at least 15 mg/kg/dose) to those treated with less than 15 mg/kg/dose. We used a general linear mixed multivariable model analysis with variables identified a priori through a conceptual framework based on the literature.
A total of 337 patients who were admitted to the three hospitals were included in the cohort. One-third of patients received vancomycin empirically at the guideline-recommended dose. Guideline-recommended dosing was not associated with in-hospital mortality in the univariable (16% vs. 13%, OR 1.26 [95%CI 0.67-2.39]) or multivariable (OR 0.71, 95%CI 0.33-1.55) analysis. Independent predictors of in-hospital mortality were ICU admission, Pitt bacteremia score of 4 or greater, age 53 years or greater, and nephrotoxicity.
Empiric use of weight-based, guideline-recommended empiric vancomycin dosing was not associated with reduced mortality in this multicenter study.